PMID- 29138929
OWN - NLM
STAT- MEDLINE
DCOM- 20180924
LR  - 20181113
IS  - 1433-8726 (Electronic)
IS  - 0724-4983 (Linking)
VI  - 36
IP  - 2
DP  - 2018 Feb
TI  - Safety and feasibility study of holmium laser enucleation of the prostate (HOLEP) 
      on patients receiving dual antiplatelet therapy (DAPT).
PG  - 271-276
LID - 10.1007/s00345-017-2129-y [doi]
AB  - OBJECTIVE: To evaluate the safety and feasibility of Holmium laser enucleation of 
      the prostate (HoLEP) in patients receiving dual antiplatelet therapy (DAPT). 
      METHODS: From March 2013 to August 2016, we retrospectively analyzed 1124 benign 
      prostatic hyperplasia (BPH) patients undergoing HoLEP and divided into four 
      groups: 56 cases receiving DAPT therapy (group A); 72 patients treated with 
      continuous single antiplatelet (AP) therapy (group B); 41 patients treated with 
      single AP therapy but intermittent during preoperative time (group C) and 955 
      cases had no AP therapy (group D). Patients' baseline characteristics, 1-year 
      clinical outcomes, rates of postoperative bleeding and complications were 
      presented in this study. RESULTS: All patients received successful operations and 
      no severe postoperative complications occurred. Only one patient in Group D 
      required transfusion. The enucleation time and catheterization time for the DAPT 
      patients were the longest among four groups (p < 0.001, respectively). The 
      overall complications rates within 30 days were 23.2% (13/56) in Group A, 27.8% 
      (20/72) in Group B, 19.5% (8/41) in Group C, and 27.0% (258/955) in Group D, 
      respectively (p = 0.678). By the 12 months, the international prostate symptom 
      scores (IPSS), quality of life scores (QOL) and residual urine volume (RUV) in 
      all groups have been significantly improved. CONCLUSION: HoLEP in patients 
      receiving DAPT after coronary artery stunting showed similar results to those 
      achieved in patients receiving single AP therapy or non-AP therapy. It can be a 
      good option, which the urologists can offer to those patients with symptomatic 
      benign prostatic hyperplasia refractory to medical treatment.
FAU - Sun, Jie
AU  - Sun J
AD  - Department of Urology, Renji Hospital affiliated to Shanghai Jiao Tong 
      University, Medical School, No 160, PuJian Road, Pudong New District, Shanghai, 
      201200, China.
FAU - Shi, An
AU  - Shi A
AD  - Department of Urology, Renji Hospital affiliated to Shanghai Jiao Tong 
      University, Medical School, No 160, PuJian Road, Pudong New District, Shanghai, 
      201200, China.
FAU - Tong, Zhen
AU  - Tong Z
AD  - Department of Urology, Renji Hospital affiliated to Shanghai Jiao Tong 
      University, Medical School, No 160, PuJian Road, Pudong New District, Shanghai, 
      201200, China.
FAU - Xue, Wei
AU  - Xue W
AUID- ORCID: 0000-0003-4672-5536
AD  - Department of Urology, Renji Hospital affiliated to Shanghai Jiao Tong 
      University, Medical School, No 160, PuJian Road, Pudong New District, Shanghai, 
      201200, China. xwrenji@126.com.
LA  - eng
PT  - Journal Article
DEP - 20171114
PL  - Germany
TA  - World J Urol
JT  - World journal of urology
JID - 8307716
RN  - 0 (Platelet Aggregation Inhibitors)
SB  - IM
CIN - World J Urol. 2020 Apr;38(4):1081-1082. PMID: 30798380
MH  - Aged
MH  - Aged, 80 and over
MH  - Case-Control Studies
MH  - Coronary Artery Disease/*drug therapy
MH  - Drug Therapy, Combination
MH  - Feasibility Studies
MH  - Humans
MH  - Laser Therapy/*methods
MH  - Lasers, Solid-State
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Postoperative Complications/epidemiology
MH  - Postoperative Hemorrhage/*epidemiology
MH  - Prostate/surgery
MH  - Prostatic Hyperplasia/*surgery
MH  - Retrospective Studies
OTO - NOTNLM
OT  - Benign prostate hyperplasia
OT  - Dual antiplatelet therapy
OT  - Holmium laser enucleation of the prostate
OT  - Lower urinary tract symptoms
EDAT- 2017/11/16 06:00
MHDA- 2018/09/25 06:00
CRDT- 2017/11/16 06:00
PHST- 2017/09/30 00:00 [received]
PHST- 2017/11/09 00:00 [accepted]
PHST- 2017/11/16 06:00 [pubmed]
PHST- 2018/09/25 06:00 [medline]
PHST- 2017/11/16 06:00 [entrez]
AID - 10.1007/s00345-017-2129-y [pii]
AID - 10.1007/s00345-017-2129-y [doi]
PST - ppublish
SO  - World J Urol. 2018 Feb;36(2):271-276. doi: 10.1007/s00345-017-2129-y. Epub 2017 
      Nov 14.